Compare iShares MSCI Indonesia ETF (EIDO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Johnson & Johnson — how do they compare? iShares MSCI Indonesia ETF trades at $12.65, while Johnson & Johnson trades at $261.08 (market cap $628.65B). The key difference: Johnson & Johnson pays a 2.05% dividend while iShares MSCI Indonesia ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | JNJ | |
|---|---|---|
52-Week High | $19.22 | $267.24 |
52-Week Low | $10.80 | $174.16 |
Market Cap | — | $628.65B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $656.92B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $12.69, down 0.47% on the day, with a bearish technical signal from moving averages and mixed oscillators. The stock faces resistance near $13 and support at $12. Recent news highlights Indonesia's economic initiatives and central bank rate hikes, but the ETF's heavy financials weighting and weak price action persist. Key financial ratios are not provided in the current dataset.
The outlook remains cautious due to technical downtrend and external pressures on Asian equities. Opportunities exist if Indonesia's AI integration and reforestation plans boost economic growth, but risks include currency volatility and limited earnings growth. Investor sentiment is neutral to bearish amid capital outflows from regional markets.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
